BCG vaccine in urinary bladder cancer.
作者信息
Brosman S A
出版信息
West J Med. 1991 Dec;155(6):633.
Abstract
摘要
相似文献
1
BCG vaccine in urinary bladder cancer.
West J Med. 1991 Dec;155(6):633.
2
BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
Prog Clin Biol Res. 1988;269:511-24.
3
The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ.
Prog Clin Biol Res. 1989;310:193-205.
4
[Treatment and follow-up of superficial bladder cancer].
Duodecim. 2002;118(9):903-9.
5
6
BCG for bladder cancer.
Med Lett Drugs Ther. 1991 Apr 5;33(841):29-30.
7
BCG in carcinoma in situ and superficial bladder tumors.
Prog Clin Biol Res. 1988;269:497-510.
8
BCG versus thiotepa in non-CIS, stage Ta, T1 bladder cancer: rationale and design of ECOG trial.
Prog Clin Biol Res. 1989;310:275-83.
9
[Our experience in the treatment of superficial cancer of the bladder with BCG].
Arch Esp Urol. 1989 May;42(4):325-7.
10
A practical guide to the use of intravesical BCG for the management of stage Ta, T1, CIS, transitional cell cancer.
Prog Clin Biol Res. 1989;310:311-23.
引用本文的文献
1
Glycoconjugate Nanoparticle-Based Systems in Cancer Immunotherapy: Novel Designs and Recent Updates.
Front Immunol. 2022 Mar 30;13:852147. doi: 10.3389/fimmu.2022.852147. eCollection 2022.
本文引用的文献
1
Mechanisms of action of intravesical bacillus Calmette-Guerin for bladder cancer.
Cancer Treat Res. 1989;46:195-211. doi: 10.1007/978-1-4613-1595-7_11.
2
Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview.
Urol Int. 1990;45(3):129-36. doi: 10.1159/000281694.
3
Intravesical bacillus Calmette-Guérin administration in the prophylaxis of superficial bladder cancer.
Int Urol Nephrol. 1990;22(5):433-40. doi: 10.1007/BF02549774.
4
Intravesical bacillus Calmette-Guerin for patients with high-risk superficial bladder cancer.
Urology. 1991 Feb;37(2):180-4. doi: 10.1016/0090-4295(91)80221-r.
Zotero 插件